Microbiological Factors and Patient-Reported Outcomes of Exacerbation Burden in Pseudomonas aeruginosa-Colonised Bronchiectasis: A One-Year Prospective Study

Background: Exacerbations are key determinants of disease progression and impaired health-related quality of life (HRQoL) in non-cystic fibrosis bronchiectasis (BE). Despite the recognised association between Pseudomonas aeruginosa (PA) and worse outcomes, factors driving exacerbation burden remain poorly characterised. In patients with PA-colonised BE, we aimed to assess whether microbiological factors, including colonisation status and PA phenotype, together with HRQoL domains and respiratory symptoms, were associated with time to first exacerbation, exacerbation severity, and post-exacerbation changes in HRQoL. Materials and Methods: This prospective longitudinal study followed PA-colonised BE adults for 12 months with quarterly stable-state assessments focussing on time and severity of first exacerbation. HRQoL was measured by the Quality of Life Questionnaire-Bronchiectasis (QOL-B). Multivariable Cox, Firth penalised logistic, and ANCOVA models were fitted in R. Results: A total of 68 patients were included. During follow-up, 52 patients (76.5%) experienced ≥1 exacerbation, including 14 (26.9%) whose first event required hospitalisation. Neither colonisation status nor PA phenotype were associated with exacerbation risk or hospitalisation. Better daytime cough (HR 0.63, 95%CI 0.41–0.97; p = 0.036) and dyspnoea while talking (HR 0.47, 95%CI 0.26–0.87; p = 0.016) were independently associated with lower exacerbation risk. Lower exertional dyspnoea burden (OR 0.29, 95%CI 0.10–0.67; p = 0.003) and lower sputum quantity (OR 0.46, 95%CI 0.19–0.93; p = 0.030) were associated with lower odds of hospitalisation, together with poorer Vitality, Social Functioning, and Health Perceptions. After exacerbation, Social Functioning declined significantly (Δ −7.50 points, 95%CI −14.87 to −0.14; p = 0.046) and mucoid PA was independently associated with worse Emotional Functioning (β −15.64, 95%CI −27.89 to −3.39; p = 0.013). Conclusions: In PA-colonised BE, selected respiratory symptoms and HRQoL domains were associated with exacerbation burden, whereas microbiological characteristics showed no clear associations with exacerbation risk or hospitalisation, supporting the incorporation of patient-reported outcomes into longitudinal assessment.

Authors

Institutions

Publication Details

Journal
Medical Sciences
Published
2026-09-22
DOI
https://doi.org/10.3390/medsci14060596
Primary Topic
Cystic Fibrosis Research Advances
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
article

Microbiological Factors and Patient-Reported Outcomes of Exacerbation Burden in Pseudomonas aeruginosa-Colonised Bronchiectasis: A One-Year Prospective Study

Nil Vázquez, Rubén López-Aladid, Leticia Bueno, Adrián Ceccato et al.
Medical Sciences
Cystic Fibrosis Research Advances
article

Microbiological Factors and Patient-Reported Outcomes of Exacerbation Burden in Pseudomonas aeruginosa-Colonised Bronchiectasis: A One-Year Prospective Study

Nil Vázquez, Rubén López-Aladid, Leticia Bueno, Adrián Ceccato, Albert Gabarrús, Laia Fernández‐Barat, Miquel Ferrer, Victoria Alcaraz-Serrano, Patricia Oscanoa-Huamán, Nestor Soler, Roberto Cabrera, Antoni Torres
article en

Abstract

Background: Exacerbations are key determinants of disease progression and impaired health-related quality of life (HRQoL) in non-cystic fibrosis bronchiectasis (BE). Despite the recognised association between Pseudomonas aeruginosa (PA) and worse outcomes, factors driving exacerbation burden remain poorly characterised. In patients with PA-colonised BE, we aimed to assess whether microbiological factors, including colonisation status and PA phenotype, together with HRQoL domains and respiratory symptoms, were associated with time to first exacerbation, exacerbation severity, and post-exacerbation changes in HRQoL. Materials and Methods: This prospective longitudinal study followed PA-colonised BE adults for 12 months with quarterly stable-state assessments focussing on time and severity of first exacerbation. HRQoL was measured by the Quality of Life Questionnaire-Bronchiectasis (QOL-B). Multivariable Cox, Firth penalised logistic, and ANCOVA models were fitted in R. Results: A total of 68 patients were included. During follow-up, 52 patients (76.5%) experienced ≥1 exacerbation, including 14 (26.9%) whose first event required hospitalisation. Neither colonisation status nor PA phenotype were associated with exacerbation risk or hospitalisation. Better daytime cough (HR 0.63, 95%CI 0.41–0.97; p = 0.036) and dyspnoea while talking (HR 0.47, 95%CI 0.26–0.87; p = 0.016) were independently associated with lower exacerbation risk. Lower exertional dyspnoea burden (OR 0.29, 95%CI 0.10–0.67; p = 0.003) and lower sputum quantity (OR 0.46, 95%CI 0.19–0.93; p = 0.030) were associated with lower odds of hospitalisation, together with poorer Vitality, Social Functioning, and Health Perceptions. After exacerbation, Social Functioning declined significantly (Δ −7.50 points, 95%CI −14.87 to −0.14; p = 0.046) and mucoid PA was independently associated with worse Emotional Functioning (β −15.64, 95%CI −27.89 to −3.39; p = 0.013). Conclusions: In PA-colonised BE, selected respiratory symptoms and HRQoL domains were associated with exacerbation burden, whereas microbiological characteristics showed no clear associations with exacerbation risk or hospitalisation, supporting the incorporation of patient-reported outcomes into longitudinal assessment.

Medical SciencesVol. 14(6)
Centro de Investigación Biomédica en Red de Enfermedades Respiratorias (ES), Hospital Clínic de Barcelona (ES), Institute of Research and Innovation Parc Tauli (ES), Institute of History (HU), Barcelona Institute for Global Health (ES), Fundació Clínic per a la Recerca Biomèdica (ES), Consorci Sanitari Garraf (ES), Universitat Ramon Llull (ES), Universitat de Barcelona (ES)
No poverty
Openalex Percentile: Top 11%
Cystic Fibrosis Research Advances
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.